Is This the Future of Drug Development with AI

Isomorphic Labs raised $600 million in its initial external funding round to enhance artificial intelligence applications in drug development. Thrive Capital led this round, supported by Google Ventures and existing investor Alphabet. Isomorphic Labs, formed from Google DeepMind in 2021, aims to advance its AI drug design engine and clinical programs. This funding follows significant raises in the AI-driven biotech sector, including Xaira Therapeutics, which secured $1 billion, and Formation Bio, which raised $372 million. Thrive Capital, co-founded by Joshua Kushner, has also led major investments in Databricks and OpenAI.Learn more on this news visit us at: https://greyjournal.net/news/ Hosted on Acast. See acast.com/privacy for more information.